Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TYR | P14679 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27981237 | 0.86 | TDP1 (0.53) | TDP1LMNATYRESR1ESR2 | |
| SCHEMBL878376 | 0.84 | PPARG (0.58) | TDP1LMNARAB9ATSHRMAPK1 | |
| SCHEMBL6696894 | 0.79 | TDP1 (0.45) | TDP1LMNATYRESR1ESR2 | |
| SCHEMBL6696898 | 0.79 | TDP1 (0.45) | TDP1LMNATYRESR1ESR2 | |
| SCHEMBL137486 | 0.79 | TDP1 (0.83) | TDP1LMNAESR1ESR2NPC1 | |
| SCHEMBL29279716 | 0.79 | TYR (0.74) | TDP1LMNATYRESR1ESR2 | |
| SCHEMBL1268522 | 0.78 | ALDH1A1 (0.40) | TDP1LMNATYRKMT2AALDH1A1 | |
| SCHEMBL16673146 | 0.78 | LMNA (0.59) | TDP1LMNATYRESR1ESR2 | |
| SCHEMBL8703432 | 0.78 | ESR1 (0.64) | TDP1LMNATYRESR1ESR2 | |
| SCHEMBL13292516 | 0.77 | TDP1 (0.79) | TDP1LMNAESR1ESR2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040186160-A1 | Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors | SUGEN, INC. | 2004-09-23 | — | — | US | disclosed |
| EP-0526529-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF SUBSTITUTED INDOLONE DERIVATIVES | SMITH KLINE FRENCH LAB (GB) | 1996-10-16 | — | — | EP | disclosed |
| US-5336781-A | Process | SMITHKLINE & FRENCH LABORATORIES LIMITED (GB) | 1994-08-09 | — | — | US | disclosed |
| EP-0526529-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF SUBSTITUTED INDOLONE DERIVATIVES. | SMITH KLINE FRENCH LAB (GB) | 1993-02-10 | — | — | EP | disclosed |
| WO-1991016306-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF SUBSTITUTED INDOLONE DERIVATIVES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1991-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186160-A1 | Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors | MAP3K15, MAP3K20, MAP3K19 | TDP1 1912/4885LMNA 4797/4885TYR 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.